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Technical Abstract
Background: Cardiovascular disease is the leading cause of death in the United States and other industrialized countries. Coronary artery disease is responsible for the majority of that mortality and associated morbidity. A major target of past research has been development of methods to screen at risk individuals for future cardiac events. The Prospective Army Coronary Calcium Study (PACC) targeted this problem using electron beam computed tomography (EBCT) to detect coronary artery calcium (CAC) [1] [2] [3] [4] . Recently, near infrared spectroscopic catheter technology (NIRS) has become available for use in humans to detect lipid in the coronary arteries. This is felt to be of primary importance in the vulnerable plaque hypothesis for precipitating coronary events [5] . It is unknown whether NIRS is useful in screening at risk individuals for future cardiac events.
Objective/Hypothesis: This proposal will compare NIRS, CAC, intracoronary ultrasound (IVUS), and angiographic findings in patients referred for cardiac catheterization as predictors for future cardiac events Study Design: Patients referred for diagnostic cardiac catheterization will be considered for inclusion in the study. Following informed consent, standard left heart catheterization will be augmented with study of the proximal coronary arteries using a combination NIRS/IVUS catheter that is FDA approved for the use described in this proposal. Registered angiographic and IVUS images, as well as NIRS chemograms will be recorded. Patients will subsequently undergo CAC scoring using EBCT and standard technique as defined in PACC. Five-year outcome data will be obtained through clinical and telephone follow-up. Cardiac outcomes will be related to CAC, IVUS, NIRS and angiographic findings using Cox proportional hazard modeling.
Relevance: This study has direct relevance to the Army's Cardiovascular Screening Program (CVSP), screening of individuals in high-risk occupations as well as to the population in general. The utility of NIRS imaging in predicting cardiovascular events has not been tested, either alone, or compared to other invasive and non-invasive modalities. When screening tests, such as CAC, are positive in an individual patient, the evaluating physician will usually review those results and decide whether or not to proceed to invasive testing. If indicated, invasive testing most often includes cardiac catheterization. This serves to define the coronary artery anatomy, left ventricular function, and the presence or absence of any flow limiting stenoses. These data serve to guide therapy that may include medication, surgery, and or percutaneous coronary intervention. In addition, they are important guides to medical waivers for duty and other occupational or professional guidance.
Statement of Work
Although this approach has become standard, it only offers definitive diagnosis and treatment guidance for fixed obstructive coronary artery lesions. Contemporary research has shown that a significant proportion of myocardial infarctions may occur in patients with minimal or no coronary artery disease on angiography. These observations, as well as post mortem pathologic studies, have led to the concept of the vulnerable plaque as an important pathophysiological mechanism in the transition of a stable patient to an unstable one [6] [7] [8] .
Although CAC as used in PACC is predictive of coronary events, power varies widely [9] . Routine studies such as CAC or even angiography offer little in identifying patients with vulnerable plaques [10, 11] .
The vulnerable plaque appears to be comprised of a lipid pool in the wall of the artery that, as suggested above, may or may not be associated with obstructive coronary artery disease. This pool is usually covered with a thin fibrous cap vulnerable to a variety of influences that may cause rupture and exposure of underlying thrombogenic material to flowing blood. This pool cannot be distinguished on angiography or even intracoronary ultrasound. Plaque rupture usually leads to acute thrombosis resulting in an acute coronary syndrome and myocardial infarction.
Appreciation of the importance of identifying the vulnerable plaque has led to a great deal of research. Both invasive and noninvasive techniques have been used in an attempt to define more detail with regard to plaque composition than is available from routine angiography alone [10] .
Promising in the array of techniques currently under investigation is the technique of near infrared spectroscopy (NIRS) [5, [12] [13] [14] [15] [16] .
NIRS utilizes catheter-based reflectance spectroscopy at the time of cardiac catheterization to yield a chemogram that can be precisely correlated with the contrast angiogram as well as intravascular ultrasound images (IVUS). A reflectance catheter is introduced into the coronary artery at the time of catheterization using a standard guide catheter and intracoronary guidewire. With pullback of the catheter, near-infrared spectral data is collected in 360 degrees and processed in an anatomic format. The chemogram reveals areas in the coronary artery wall and in atherosclerotic lesions that contain pools of cholesterol and related compounds. These areas are felt to represent the nidus of the vulnerable plaque.
This methodology has been extensively validated in vitro and on human coronary artery specimens and has been FDA approved for use in humans to detect abnormalities in the coronary arteries. Such abnormalities include, but are not limited to, pools of lipid, stenosis and structural changes seen on ultrasound. Identification of lipid pools using this technology has been predictive of peripheral cholesterol embolization during percutaneous intervention as well as the no reflow phenomenon [17] . These observations highly support its utility in identifying potential vulnerable plaque in both patients with obstructive and non-obstructive coronary disease.
Clinical outcomes of patients with positive chemograms using NIRS have not been documented or compared with other methods.
Hypotheses
 NIRS detection of lipid pools in coronary arteries is predictive for adverse cardiovascular outcomes in patients referred for diagnostic cardiac catheterization.
 NIRS detection of lipid pools in coronary arteries is superior to CAC, IVUS, angiographic and Framingham risk score predictors.
Technical Objectives
 To define the prevalence of NIRS detected lipid pools in patients referred for coronary angiography.
 To relate the prevalence of obstructive coronary disease defined by angiography to the prevalence of NIRS detected lipid pools in the same patient.
 To relate the prevalence of CAC defined by EBCT to the prevalence of NIRS detected lipid pools in the same patient.
 To relate coronary morphology as defined by IVUS to the prevalence of NIRS detected lipid pools in the same patient.
 To compare the predictive value of the Framingham Risk Score, NIRS detected lipid pools, CAC defined by EBCT, coronary morphology as defined by IVUS, and coronary angiographic morphology for adverse cardiac events.
Project Milestones
 Year One Quarter One: Assigning study personnel, acquisition of equipment, physician and staff training and implementation of standard operating procedures for the study. 
Military Significance
Cardiovascular disease has long been an important issue for the Armed Forces of the United States [1-4, [18] [19] [20] [21] . This stems, not only from the incidence and prevalence of the disease, but also the importance of screening servicemen and women in hazardous duty, high stress environments, and mission-critical positions. An integral part of aviation medical screening and that for the astronaut corps involves cardiovascular function.
As currently implemented, algorithms for cardiovascular military clearance rely on noninvasive testing leading to possible cardiac catheterization. These have been referred to above.
Although a significant number of active duty personnel undergo cardiac catheterization, no prospective screening for detection of vulnerable plaque by near infrared spectroscopy or other techniques is being used.
Detection of these coronary lesions may offer significant value in guiding therapy for such individuals, determining their mission readiness, and protection of military resources. This may prove of special value in aeromedical evaluation.
This project is an observational study that will relate the presence or absence of vulnerable plaque as detected by near infrared spectroscopy to adverse cardiac outcomes. This has special relevance to screening individuals in highrisk occupations such as aeromedical evaluation of pilots.
Public Purpose
Military application, as defined above, applies to the general public without modification due to the previously mentioned importance of coronary artery disease in the population at large.
Methods
The study involves utilization of an FDA approved intra-coronary near infrared spectroscopy unit in the setting of clinically indicated cardiac catheterization. These patients will receive spectroscopic study as well as standard angiography. Studies will be done in the cardiac catheterization laboratories of Florida Hospital Pepin Heart Institute. Institutional Review Board approval and informed consent from all patients will be obtained.
Recruitment of Patients and Screening
This is a single center observational study at Florida Hospital Pepin Heart Institute and the Dr. Kiran C. Patel Research Institute in Tampa, Florida.
Patients for this study will be recruited from those referred for elective diagnostic cardiac catheterization at PHH. As is current practice for the institution, inpatients and outpatients who may be candidates for research will be screened during daily research rounds by research coordinators and the principal investigator. The local IRB will be asked for Partial Waiver of Authorization to use protected health information (PHI) for screening using the catheterization laboratory log. Screening activity is recorded using the screening log in the appendix.
If a patient is identified as a possible candidate for the study, the attending physician will be contacted for approval and, if given, the patient will be approached and educated regarding the study in the pre-procedural area or at the bedside for inpatients. Patients will be educated by Dr. Lambert and the associated clinical research coordinator. Informed consent will then be obtained.
Inclusion Criteria
1. Subject is at least 21 years of age. 2. Subject is scheduled for a clinically indicated left heart catheterization. 3. Subject is willing and able to provide informed consent prior to the index catheterization. 4. Use of the LipiScan™system is not contraindicated.
Exclusion Criteria
1. Subject life expectancy at the time of cardiac catheterization is less than three years. 2. Subject is pregnant or suspected to be pregnant.
Cardiac Catheterization
Cardiac catheterization will be performed using standard technique. Following coronary angiography and left ventricular angiography, a 6 French guide catheter will be utilized for simultaneous IVUS and NIRS acquisition in the proximal to mid left anterior descending, circumflex, left main and right coronary arteries. These images will be obtained using standard laboratory protocol and stored for later archival.
NIRS and IVUS
The LipiScan™ and LipiScan™ IVUS Coronary Imaging System will be used for this study. This is the only available system for NIRS in humans. The console component of the LipiScan and LipiScan IVUS systems perform several functions. In brief, it provides (a) the near-infrared light source for spectroscopy, (b) a data-processing system that analyzes the signals returned from the catheter, (c) a user interface to the system, (d) a means of data storage, and (e) communication to the pullback device which drives the automated scanning of the catheter imaging core, (f) in the case of the LipiScan IVUS system. Additionally, the LipiScan IVUS console includes a piezo transducer to generate and receive acoustic energy for ultrasound.
Following pullback of the catheter through the artery, the system software displays a map in the form of a graphical representation indicating the likelihood that a lipid core containing plaque is present. This map is called a chemogram. It approximates an image of the artery as if viewed with a nearinfrared camera from within the catheter. Additionally, the system software allows the operator to review previous patient procedures as well as store these procedures to CD/DVD for remote review or report generation.
The pullback rotation system (PBR) interfaces between the rotating catheter imaging core and the non-rotating components of the system. The catheter snaps into a socket on the face of the PBR, which completes the optical connections and allows for the unit to simultaneously actuate the inner imaging core and stabilize the catheter outer sheath. The longitudinal motion of the PBR permits only a distal-to-proximal automated pullback at a rate of 0.5 mm/sec. Manual movement of the imaging core is possible in either direction. The catheter core can be pulled back and rotated proximally over a total length of 15 cm.
The LipiScan™ IVUS Coronary Imaging Catheter is a single-use, disposable coronary catheter. The catheter is 3.2 F in diameter and 160 cm in usable length. The catheter is intended to be introduced into the vasculature via a 0.014-inch coronary guidewire, which is allowed to exit approximately 25 mm proximal to the distal tip. Two low-profile polymer markers are placed on the stiff proximal shaft to aid the user in locating the exit of the distal tip through the tip of a guiding catheter. This system is in use for standard clinical evaluation of patients with coronary artery disease.
EBCT
For the measurement of CAC, EBCT will be performed using an Imatron C-150 LXP scanner calibrated daily with air and water phantoms. Images will be obtained using a 40-to 50-slice (3 mm thickness) protocol with image acquisition triggered to 60% to 80% of the electrocardiographic RR interval while respirations are held. Scans will be interpreted in a blinded manner using the Agatston scoring method.
EBCT will be performed when convenient for the patient but within 2 weeks of the index catheterization. This is related to the research and may be opted out of if the patient desires to participate only in the cardiac catheterization portion of the study.
Patient Follow--up
Patients will be followed by an experienced nurse coordinator using a structured interview process and the Seattle Angina Questionnaire (appendix). Adverse cardiac events will be corroborated with source documents whenever possible. Patients will be contacted by phone at 6 month intervals. Adverse events related to the study will include those temporally related to performance of the research procedure up to two weeks following the index cardiac catheterization. These will include coronary injury including dissection, perforation or occlusion, death, cerebrovascular accident, myocardial infarction and arrhythmia requiring treatment. All medications will be recorded at enrollment and follow-up points on the follow-up database form (appendix).
Outcome
The patient data collection script for phone follow-up is included in the appendix.
Risks and Benefits
Patients included in this study are already undergoing clinically indicated cardiac catheterization with the inherent risks of that procedure. These include death, cerebrovascular accident, bleeding, infection, arrhythmia, access site damage, coronary dissection, coronary thrombosis and myocardial infarction, among others.
The risks of further coronary instrumentation with the Lipiscan™ IVUS Coronary Imaging Catheter are identical to those listed above, however, slightly higher in magnitude since a guidewire system is used to allow imaging within the arteries. The risk of any complication from procedures of this type is widely quoted as less than 1 in 1000 for experienced centers.
There is a slightly increased use of X-ray imaging used for the catheterization portion of the study and for EBCT if the patient does not opt out of that portion. Local IRB policy mandates estimation of that risk (see appendix for policy) 4 .
Benefits from the imaging performed in this investigation may include prognostic information related to the likelihood of procedural complications from percutaneous coronary intervention, should one be performed 5 
Serious Adverse Event and Adverse Event Reporting
All unanticipated problems involving risk to subjects or others, serious adverse events related to participation in the study and subject deaths related to participation in the study should be promptly reported by phone (301-619-2165), by email (hsrrb@det.amedd.army.mil), or by facsimile (301-619-7803) to the USAMRMC, Office of Research Protections, Human Research Protection Office.
Local SAE requirements are included in the SAE reporting form included in the appendix. All local SAEs are to be reported using that form to the local IRB within 10 days of the event.
Additional Reporting Requirements
A complete written report will follow the initial notification. In addition to the methods above, the complete report will be sent to the U.S. Army Medical Research and Materiel Command, ATTN: MCMR-ZB-PH, 504 Scott Street, Fort Detrick, Maryland 21702-5012.
The protocol will be conducted in accordance with the protocol submitted to and approved by the ORP HRPO and will not be initiated until written notification of approval of the research project is issued by the ORP HRPO.
The knowledge of any pending compliance inspection/visit by the FDA, DHHS-OHRP, or other government agency concerning clinical investigation or research, the issuance of Inspection Reports, FDA Form 483, warning letters or actions taken by any Regulatory Agencies including legal or medical actions and any instances of serious or continuing noncompliance with the regulations or requirements will be reported immediately to ORP HRPO.
Data Analysis and Confidentiality
Accurate and complete study records will be maintained and made available to representatives of the U.S. Army Medical Research and Materiel Command. These representatives are authorized to review research records as part of their responsibility to protect human research volunteers. Research records will be stored in a confidential manner so as to protect the confidentiality of subject information
Data Storage and Case Report Forms
The case report form set for each individual patient will consist of the following:
1. Measurement Database Input Form 2. Copy of index cardiac catheterization report 3. Baseline Seattle Angina Questionnaire 4. Follow-up database and Seattle Angina Questionnaire completed every six months until study completion.
Data storage will be kept on a password protected non-networked computer in a password protected Filemaker-Pro database containing the elements defined above. Backups will consist of routine weekly optical backup as well as hard copy storage in the secure data archival area at the Dr. Kiran C. Patel Research Institute.
Data access will be restricted to the principal investigator, Janice Shirley and the assigned clinical research coordinator.
Hard copy data will be retained for seven years. Janice Shirley is responsible for data retention and destruction.
Data Analysis
Coronary Angiograms: Angiograms will be analyzed by Dr. Lambert documenting the presence or absence of coronary artery disease (CAD) in proximal, mid-, and distal segments of all three major coronary arteries as well as the left main artery.
Categorical data will include the presence or absence of significant disease. Specific lesions will be analyzed utilizing quantitative angiography (General Electric DMS) for continuous data including percent stenosis, minimum lumen diameter, lesion length, presence of calcification, and reference vessel diameter. Left ventricular angiography will be analyzed utilizing Simpson's rule methodology for global and regional function. Categorical data will include normal or abnormal function and continuous data will include ejection fraction.
IVUS: Pullback images will be analyzed by Dr. Lambert in proximal, mid-, and distal segments of all three major coronary arteries as well as the left main artery.
Measurements will include EEM diameter, EEM area, vessel lumen diameter, vessel lumen area, plaque+media thickness, plaque+media area, lumen perimeter, calcium length, stenotic lesion length, lumen eccentricity index, plaque+media eccentricity index, remodeling index, lumen shape index, lumen diameter ratio, EEM diameter ratio, EEM volume, lumen volume, native plaque volume, total plaque volume, calcium distribution, lesion morphology, and plaque composition if estimable.
EBCT: Scanning and analysis will follow the methodology of the PACC Study [1] . See the EBCT section above for methods.
Framingham Risk Scores (FRS): The predicted 10-year FRS for incident CHD will be calculated using measured risk factor variables as specified within regression equations from the Framingham Heart Study [22] .
NIRS: As described in validations studies, the lipid core burden index will be determine for each arterial segment interrogated (identical to IVUS segments). This index will analyzed as a continuous variable.
Statistical Analysis: The prevalence of most variables defined above has not been defined for an all-inclusive catheterization population as that used in the present study. In particular, the prevalence of NIRS detected lipid pools is unknown. Thus, sample size considerations (630) are based on those useful in the PACC study that assumes a prevalence of 23% to estimate the true prevalence (technical objective one) with a 95% confidence of ±2%.
For univariate analyses, continuous variables will be compared using the t test for independent groups and categorical variables using the chi-square test. Multivariate analysis will be performed using Cox proportional hazards modeling and stepwise methods to examine the independent predictive value of NIRS scores, CAD severity, IVUS metrics, and CAC in tertiles for adverse cardiac events. Standard forward and backward analyses will be performed.
Significance of the Research
The ability to detect vulnerable plaque and intervene with medical or mechanical therapy to prevent transition from a stable to an unstable clinical state would represent significant advancement in treatment of patients with coronary disease [23] . Application of near infrared spectroscopy to characterization of the coronary arterial wall represents a promising approach to this problem [5] .
The undetected vulnerable plaque represents a potentially catastrophic lesion in individuals with high-risk occupations. This risk stems from not only the unpredictability of plaque rupture, but also the very nature of the stressors felt to be important in this conversion. These include hemodynamic stress, mental stress, acute hormonal changes, and others [24] . Many of these potential facilitators of plaque rupture are indeed associated themselves with high-risk occupations and hazardous duty. 
Duration of the Project
The initial duration of this project will be five years.
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